National Institute of Neurological Disorders and Stroke (NINDS)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).

567 total trials 48 currently recruiting 467 completed early-phase tilt top decile by trial count

National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.

National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.

Top-decile sponsor footprint

National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 70/100

467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

567 total, page 8 of 12

COMPLETED

Magnetic Resonance Imaging of the Brain in Social and Emotional Reasoning

NCT00060853

COMPLETED

Hypnosis in Autonomic Function

NCT00061009

COMPLETED

Magnetic Resonance Imaging of the Brain in Emotional Processing

NCT00061204

TERMINATED

Evaluation of Primary Chronic Autonomic Failure

NCT00059033

COMPLETED

Brain Plasticity of Verbal Memory in the Blind

NCT00059189

COMPLETED Phase 2

Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity

NCT00057460

COMPLETED

The Role of Gene Changes in Brain Tumor Formation and Growth

NCT00059020

COMPLETED

Postural Control in the Elderly

NCT00059501

COMPLETED

Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease

NCT00058721

COMPLETED

Development of Techniques for Use in MRI With a Magnetic Field of 7 Tesla

NCT00056914

COMPLETED

Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders

NCT00056888

COMPLETED

Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement

NCT00056420

COMPLETED Phase 1

Nervous System Function in Normal Volunteers During Cycling Training

NCT00055588

COMPLETED Phase 1

Dextromethorphan to Treat Patients With Voice Spasms

NCT00055549

COMPLETED Phase 2

Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease

NCT00082342

COMPLETED

Ischemic Nerve Block to Improve Hand Function in Stroke Patients

NCT00056706

COMPLETED

Registry of Fabry Disease - A Multicenter Observational Study

NCT00055016

COMPLETED

Brain Use of Sensory Information to Generate Movement

NCT00055289

COMPLETED

Survey of Sensory and Motor Tricks in Focal Dystonia

NCT00054652

COMPLETED

Effects of Antiepileptic Drugs on Brain Excitability

NCT00054990

COMPLETED

Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome

NCT00051961

COMPLETED

Single Photon Emission Computed Tomography (SPECT) to Study Paroxysmal Hyperkinetic Movement Disorders

NCT00051337

COMPLETED

Brain Encoding for Memory

NCT00051870

COMPLETED Phase 3

Minocycline to Treat Amyotrophic Lateral Sclerosis

NCT00047723

COMPLETED

Learning a Motor Task Through Observation

NCT00050869

COMPLETED Phase 2

Rituximab to Treat Neuropathy With Anti-MAG Antibodies

NCT00050245

COMPLETED Phase 1

Preliminary Study of Transcranial Magnetic Stimulation for Stroke Rehabilitation

NCT00050128

COMPLETED

Transcranial Magnetic Stimulation and Electrical Stimulation of Nerves to Study Focal Dystonia

NCT00050024

COMPLETED Phase 2

Alpha-Galactosidase A Replacement Therapy for Fabry Disease

NCT00048906

COMPLETED Phase 1

Effects of Direct Current Brain Stimulation on Cognition

NCT00048698

COMPLETED

Brain Inhibition of Muscle Movement in Normal Volunteers

NCT00047957

COMPLETED Phase 2

Transcranial Magnetic Stimulation to Treat Epilepsy

NCT00048490

COMPLETED

Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting

NCT00046410

COMPLETED Phase 2

ReoPro and Retavase to Treat Acute Stroke

NCT00046293

COMPLETED

Transcranial Magnetic Stimulation to Study Imagination of Movement

NCT00046215

COMPLETED

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252

COMPLETED Phase 2

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease

NCT00041535

COMPLETED

How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance

NCT00040196

COMPLETED

MRI Language Studies in Young Children

NCT00039845

COMPLETED

Genetic Studies to Identify Stroke Subtypes and Outcome

NCT00357513

COMPLETED Phase 2

JP-1730 to Treat Parkinson's Disease

NCT00040209

COMPLETED

Nerve Stimulation to Modify a Spinal Reflex

NCT00039819

COMPLETED Phase 2

Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

NCT00342134

COMPLETED NA

Hypothermia to Treat Severe Brain Injury

NCT00040339

COMPLETED

Functional Coupling of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control

NCT00036595

COMPLETED

Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome

NCT00034398

COMPLETED

Magnetic Resonance Imaging in Children and Adults Using Arterial Spin Tagging Techniques

NCT00034073

COMPLETED

Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder

NCT00033995

COMPLETED Phase 2

High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration

NCT00034242

COMPLETED

MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

NCT00034723

← Previous Page 8 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 78
Phase 3 11
Phase 4 5

What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline

48 recruiting of 567 indexed (8% open); 467 completed (82%).

Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).

Top condition: Healthy (23 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide

Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share National Institute of Neurological Disorders and Stroke (NINDS)Children's Hospital Medical Center, CincinnatiUniversity of Maryland, BaltimoreAmgenMerck Sharp & DohmeNational Jewish HealthACADIA PharmaceuticalsTexas Tech University Health Sciences Center, El PasoBoehringer Ingelheim
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 567 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page

567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.

  • 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.